Details of the Drug Combinations

General Information of This Drug (ID: DMDZ6Q3)

Drug Name

Napabucasin DMDZ6Q3

Synonyms

83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919

Indication

Disease Entry	ICD 11	Status	REF
Colorectal cancer	2B91.Z	Phase 3	[1]
Pancreatic cancer	2C10	Phase 3	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 3	[2]
Advanced malignancy	2A00-2F9Z	Phase 1/2	[1]
Gastrointestinal cancer	2C11	Phase 1/2	[1]
Hepatocellular carcinoma	2C12.02	Phase 1/2	[1]
Recurrent glioblastoma	2A00.00	Phase 1/2	[3]
Recurring respiratory infection	CA07-CA45	Phase 1/2	[1]
Haematological malignancy	2B33.Y	Phase 1	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Napabucasin + Marizomib	DC1BFKW	Marizomib	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
------------------------------------------------------------------------------------

10 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Dexamethasone + Napabucasin	DC3UGXZ	Dexamethasone	Hematologic Malignancy	[5]
Napabucasin + Capecitabine	DCSV088	Capecitabine	Colorectal Cancer	[6]
Napabucasin + Oxaliplatin	DCX2CN8	Oxaliplatin	Advanced Gastrointestinal Cancer	[7]
Napabucasin + Imatinib	DC6IWKC	Imatinib	Hematologic Malignancy	[5]
Napabucasin + Ibrutinib	DC6U9X7	Ibrutinib	Hematologic Malignancy	[5]
Napabucasin + Temozolomide	DCBQB3J	Temozolomide	Glioblastoma	[8]
Napabucasin + Irinotecan	DCQVJK6	Irinotecan	Advanced Gastrointestinal Cancer	[7]
Napabucasin + Regorafenib	DCUBM47	Regorafenib	Advanced Gastrointestinal Cancer	[7]
Napabucasin + Paclitaxel	DCWM28L	Paclitaxel	Oncology	[9]
Napabucasin + Bortezomib	DCXG9QI	Bortezomib	Hematologic Malignancy	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 DrugCom(s)

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	First-in-Class Cancer Stemness Inhibitor Shows Promising Results in Advanced Colorectal Cancer. 2016 ASCO GI Conference. January 26, 2016.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
5	ClinicalTrials.gov (NCT02352558) A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies
6	ClinicalTrials.gov (NCT01776307) A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
7	ClinicalTrials.gov (NCT02024607) A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
8	ClinicalTrials.gov (NCT02315534) A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma
9	ClinicalTrials.gov (NCT04299880) Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols